Abstract
Flavonoids have shown anticarcinogenic activity in cancer cell lines, animal models, and some human studies. Quantitative structure-activity relationship (QSAR) models have become useful tools for identification of promising lead compounds in anticancer drug development. However, epidemiological and clinical studies are still scarce. Compounds with flavonoid scaffold have been the subject of many mechanistic studies in cells, but information on human chemopreventive properties is still missing. The knowledge of the mechanisms of action, anti-multidrug resistance, and QSAR studies on flavonoids and related compounds may help to enhance research on these compounds and their bioactivity. Therefore, once the issue is introduced, the mechanisms involved, and QSAR studies developed to predict the activity and toxicity of these chemicals to biological systems are discussed. QSAR studies on flavonoids as inhibitors of breast cancer resistance protein (BCRP/ABCG2), 17β-hydroxysteroid dehydrogenase (17β-HSD), PIM-1 kinase and cyclin-dependent kinases (CDKs) are analyzed. Combined treatment of flavonoids with TRAIL and current chemotherapy agents is also discussed as a promising cancer chemoprevention and/or therapy.
Keywords: Anticarcinogens, flavonoids, (iso)flavones, flavanones, catechins, chalcones, QSAR, theaflavins, TRAIL, flavonoids/TRAIL, flavonoids/chemotherapy
Current Medicinal Chemistry
Title:(Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Volume: 19 Issue: 25
Author(s): Andrew G. Mercader and Alicia B. Pomilio
Affiliation:
Keywords: Anticarcinogens, flavonoids, (iso)flavones, flavanones, catechins, chalcones, QSAR, theaflavins, TRAIL, flavonoids/TRAIL, flavonoids/chemotherapy
Abstract: Flavonoids have shown anticarcinogenic activity in cancer cell lines, animal models, and some human studies. Quantitative structure-activity relationship (QSAR) models have become useful tools for identification of promising lead compounds in anticancer drug development. However, epidemiological and clinical studies are still scarce. Compounds with flavonoid scaffold have been the subject of many mechanistic studies in cells, but information on human chemopreventive properties is still missing. The knowledge of the mechanisms of action, anti-multidrug resistance, and QSAR studies on flavonoids and related compounds may help to enhance research on these compounds and their bioactivity. Therefore, once the issue is introduced, the mechanisms involved, and QSAR studies developed to predict the activity and toxicity of these chemicals to biological systems are discussed. QSAR studies on flavonoids as inhibitors of breast cancer resistance protein (BCRP/ABCG2), 17β-hydroxysteroid dehydrogenase (17β-HSD), PIM-1 kinase and cyclin-dependent kinases (CDKs) are analyzed. Combined treatment of flavonoids with TRAIL and current chemotherapy agents is also discussed as a promising cancer chemoprevention and/or therapy.
Export Options
About this article
Cite this article as:
G. Mercader Andrew and B. Pomilio Alicia, (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies, Current Medicinal Chemistry 2012; 19 (25) . https://dx.doi.org/10.2174/092986712802884277
DOI https://dx.doi.org/10.2174/092986712802884277 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients
Current Radiopharmaceuticals Antisense Strategies in Therapy of Gliomas
Current Signal Transduction Therapy Editorial (Thematic Issue: <i>In Silico</i> Drug Design and Medicinal Chemistry)
Current Topics in Medicinal Chemistry CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Expression Level and Hormonal Regulation of ABC Transporters in Breast Cancer
Current Cancer Therapy Reviews Radix Stephaniae Tetrandrine: An Emerging Role for Management of Breast Cancer
Current Pharmaceutical Design Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics The Influence of Ionizing Radiation on Exosome Composition, Secretion and Intercellular Communication
Protein & Peptide Letters Nucleic Acids as Targets for Antitelomerase Agents
Mini-Reviews in Medicinal Chemistry Breast Cancer Diagnosis in Digital Mammography Images Using Automatic Detection for the Region of Interest
Current Medical Imaging BRCA Unclassified Variants: How Can They be Classified?
Current Women`s Health Reviews Synthesis and Activity of N-Sulfonylamides of Tripeptides as Potential Urokinase Inhibitors
Protein & Peptide Letters Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Network Pharmacology: Reigning in Drug Attrition?
Current Drug Discovery Technologies Genetically Engineered Elastin-based Biomaterials for Biomedical Applications
Current Medicinal Chemistry Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery